Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

0
Player Avatar pjani06 (45.90) Submitted: 3/10/2010 8:29:20 PM : Outperform Start Price: $4.87 PGNX Score: +58.34

biotech plays that zzlangerhans is behind on & picks that the CAPs community agrees with via star rating.
GREENthumb: ARNA, PGNX, ARRY, GENZ, CEPH, CPD, MYGN, ELN
REDthumb: PLX, ITMN, CLDA, PCYC

Featured Broker Partners


Advertisement